The title of Dr. Mehling’s presentation is “Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury.”
Spinal cord injury (SCI) is a common type of severe trauma often resulting in a permanent neurologic deficit. The current retrospective cohort study is aimed to analyze the muscle, nerve, urinary, and gastrointestinal function in SCI subjects treated with either human Umbilical Cord Blood Mononuclear Cells (hUCMNCs) or conventional therapy. Thirty patients with spinal cord injury were randomly selected from seventy treated with hUCMNCs between March 2009 and March 2012. Another thirty patients with SCI, who received only traditional therapy and no stem cell therapy, were included as the control group.
This study was approved by an Institutional Review Board of the Wright State University (Office of Research and Sponsored Programs. SC# 5488, “Spinal Cord Injury Stem Cell Therapy”).
A significantly higher proportion of subjects in the hUCMNCs therapy group showed improved function in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group.
More information about the summit can be found here: https://www.worldbrainmapping.org/G20-World-Brain-Mapping-Therapeutics-Initiative/
To View the Program please click below:
Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It happens when the protective cartilage that cushions your bones wears down over time. Osteoarthritis most commonly affects hands, knees, hips, and spine. Researchers and clinicians from BHI Therapeutic Sciences, USA and Blue Horizon International, Slovakia recently concluded cell-based therapy shows promising results in the regeneration of injured cartilage and serves as an anti-inflammatory for the affected joint.
The paper, “A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis” was recently published in the Journal of Clinical Medicine Research.
“Our study of 350 subjects with hip and knee osteoarthritis showed a significant improvement in pain levels and mobility at 3, 6, and 12 months compared to 7 days after autologous stromal vascular fraction (SVF) cell therapy,” said Brian Mehling, M.D., one of the authors of the study and the chief medical officer of BHI Therapeutic Sciences.
The study was approved by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2-17-137) and by the Ministry of Health of the Slovak Republic.
“The treatment demonstrated a strong safety profile with no severe adverse events or complications reported,” said Marina Manvelyan, Ph.D., clinical research scientist at BHI Therapeutic Sciences. “Interestingly, the results of the study show that SVF cell therapy was more effective in subjects with arthritis stage III compared to arthritis stages I, II, and IV,” she added.
The authors of the paper are Brian Mehling, Milan Hric, Adriana Salatkova, Robert Vetrak, Doreen Santora, Miriama Ovariova, Renata Mihalyova, and Marina Manvelyan.
BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.
The Journal of Clinical Medicine is an international, open access, and peer-reviewed journal that concentrates on general medical research and clinical practice. The journal aims to publish scientifically written, evidence-based articles from all disciplines of medical sciences and clinical practice, and nursing, preventive medicine, epidemiology, healthcare research, etc. All articles are rigorously peer-reviewed. The journal is indexed in PubMed and PubMed Central (PMC, US National Library of Medicine National Institutes of Health).
To read the study, visit bluehorizonstemcells.com.
Researchers need to modify genes in cells if they are to find out about life’s inner workings. This used to be time-consuming, difficult and sometimes impossible work. Using the CRISPR/Cas9 genetic scissors, it is now possible to change the code of life over the course of a few weeks. Emmanuelle Charpentier and Jennifer A. Doudna have discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and microorganisms with extremely high precision. This technology has had a revolutionary impact on the life sciences, is contributing to new cancer therapies and may make the dream of curing inherited diseases come true.
LA TOKEN has just announced what could be arguably the most appealing Initial Exchange Offering in the past decade.
It features a stem cell technology backed coin named “Stemy Coin” that is seeking FDA approval for COVID 19 stem cell treatment solutions based not only on the immunomodulatory and anti-inflammatory capacity of stem cells, but also regeneration and reconstruction of damaged tissues.
BHI and Stem Cell Biotech have successfully treated 34 coronavirus patients in Wuhan. This Stem Cell technology has also been proven to effectively address cancer, strokes, heart attacks, diabetes, kidney, liver, and lung disease. GDIH First Response and Stem Cell Biotech will be rolling out 100 clinics around the world, in partnership BHI to combat Covid-19 worldwide. This could be the fastest rising digital currency in the blockchain industry.